Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · December 11, 2024

Safety and Efficacy of Deucravacitinib Over 3 Years in Patients With Moderate to Severe Plaque Psoriasis

JAMA Dermatology

 

Additional Info

JAMA Dermatology
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials
JAMA Dermatol 2024 Nov 27;[EPub Ahead of Print], AW Armstrong, M Lebwohl, RB Warren, H Sofen, S Imafuku, M Ohtsuki, L Spelman, T Passeron, KA Papp, RM Kisa, J Vaile, V Berger, E Vritzali, K Hoyt, MJ Colombo, J Scotto, S Banerjee, B Strober, D Thaçi, A Blauvelt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading